可切除胃腺癌新辅助化疗对比化疗联合放化疗的多中心分析
该多中心回顾性研究比较可切除胃腺癌患者接受新辅助化疗(CT)与新辅助化疗联合放化疗(CRT)的疗效,经倾向性匹配各113例分析,CRT组病理完全缓解率更高(15% vs 4%,p=0.003)、病理分期更低(p=0.002)、围术期治疗完成率更高(91% vs 63%,p<0.001),中位无病生存期(113 vs 45个月,p=0.018)和中位总生存期(120 vs 53个月,p=0.015)均更优。
要点
- CRT组病理完全缓解率15%,显著高于CT组4%(p=0.003)。
- CRT组围术期治疗完成率91%,高于CT组63%(p<0.001)。
- CRT组中位OS 120个月,优于CT组53个月(p=0.015)。
核心结论
- 可切除胃腺癌新辅助化疗联合放化疗较单纯化疗提高病理完全缓解率、围术期治疗完成率并改善生存。
主要发现
- CRT组与CT组显微镜下切缘阴性率相似(93% vs 91%,p=0.81)。
- CRT组病理完全缓解率高于CT组(15% vs 4%,p=0.003),病理分期更低(p=0.002)。
- 围术期治疗完成率CRT组91%,CT组63%(p<0.001)。
- 中位DFS在CT组为45个月(95%CI 20-70),CRT组为113个月(95%CI 75-151),p=0.018。
- 中位OS在CT组为53个月(95%CI 30-77),CRT组为120个月(95%CI 101-138),p=0.015。
关键数值与推荐
- 倾向性匹配队列:CT组113例,CRT组113例。
- CRT组病理完全缓解率15%,CT组4%(p=0.003)。
- CRT组围术期治疗完成率91%,CT组63%(p<0.001)。
- CRT组中位DFS 113个月(95%CI 75-151),CT组45个月(95%CI 20-70),p=0.018。
- CRT组中位OS 120个月(95%CI 101-138),CT组53个月(95%CI 30-77),p=0.015。
临床怎么用
- 对于可切除胃腺癌,新辅助化疗联合放化疗可作为提高病理缓解率和生存的备选策略,但需结合患者耐受性个体化选择。
局限性
- 回顾性多中心设计,证据等级为Level III。
- 两组基于组织病理学特征存在差异(术前分期p=0.013),虽经倾向性匹配但仍可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We compare neoadjuvant chemotherapy (CT) to neoadjuvant chemotherapy plus chemoradiation (CRT) for patients with gastric adenocarcinoma (GA). SUMMARY OF BACKGROUND DATA: The optimal neoadjuvant therapy regimen for resectable GA is not defined. METHODS: Utilizing data from 2 high-volume cancer centers, we analyzed patients who underwent surgery for localized GA from 1/1/2000-12/31/2017. Standard CT regimens were used according to treatment period. We compared propensity matched cohorts based on age, sex, race, histology, and clinical stage. RESULTS: Four-hundred five patients (age 62 ± 12 year, 58% male, 56% White) were analyzed. 231 (57%) received CRT and 174 (43%) received CT. Groups differed based on histopathologic characteristics including preoperative stage (p = 0.013). To control for these differences, propensity matched cohorts of 113 CT and 113 CRT patients were compared. CRT had similar frequencies of microscopically negative resections to CT (93% vs 91%, p = 0.81), but higher rates of complete pathologic response (15% vs 4%, p = 0.003) and lower pathologic stage (p = 0.002). Completion of intended perioperative therapy occurred in 63% of CT and 91% of CRT patients (p < 0.001). Median DFS was 45mo (95%CI: 20-70) in the CT group and 113mo (95%CI: 75-151) in the CRT group (p = 0.018). Median OS was 53mo (95%CI: 30-77) versus 120mo (95%CI: 101-138); p = 0.015. CONCLUSIONS: In this multi-institutional comparison of neoadjuvant CT and CRT for resectable GA, CRT is associated with higher rates of completed perioperative therapy, higher rates of complete pathologic response, lower pathologic stage, and improved survival.Level of Evidence: Level III.
引用
- Allen CJ, Pointer DT, Blumenthaler AN, et al. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional Analysis. Ann Surg. 2021. PMID: 34132693. doi:10.1097/SLA.0000000000005007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。